Bristow MR - Search Results

1

Beta-blocking agents in heart failure. Should they be used and how?

Cleland JG, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Cleland JG, et al. Among authors: bristow mr. Eur Heart J. 1996 Nov;17(11):1629-39. doi: 10.1093/oxfordjournals.eurheartj.a014745. Eur Heart J. 1996. PMID: 8922910 Review.

2

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.

Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Gilbert EM, et al. Among authors: bristow mr. Am J Med. 1990 Mar;88(3):223-9. doi: 10.1016/0002-9343(90)90146-5. Am J Med. 1990. PMID: 1968710 Clinical Trial.

3

The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure.

Bristow MR, Port JD, Hershberger RE, Gilbert EM, Feldman AM. Bristow MR, et al. Eur Heart J. 1989 Jun;10 Suppl B:45-54. doi: 10.1093/eurheartj/10.suppl_b.45. Eur Heart J. 1989. PMID: 2572420 Review.

4

Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart.

Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Gilbert EM, et al. Among authors: bristow mr. Chest. 1995 Dec;108(6):1524-32. doi: 10.1378/chest.108.6.1524. Chest. 1995. PMID: 7497755

5

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Waagstein F, et al. Among authors: bristow mr. Lancet. 1993 Dec 11;342(8885):1441-6. doi: 10.1016/0140-6736(93)92930-r. Lancet. 1993. PMID: 7902479 Clinical Trial.

6

Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.

Bristow MR. Bristow MR. Am J Cardiol. 1993 Mar 25;71(9):12C-22C. doi: 10.1016/0002-9149(93)90082-n. Am J Cardiol. 1993. PMID: 8096671 Review.

7

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure.

Bristow MR, Gilbert EM. Bristow MR, et al. Eur Heart J. 1995 Jul;16 Suppl F:20-31. doi: 10.1093/eurheartj/16.suppl_f.20. Eur Heart J. 1995. PMID: 8521881 Review.

8

Cardiac adrenergic receptor effects of carvedilol.

Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Yoshikawa T, et al. Among authors: bristow mr. Eur Heart J. 1996 Apr;17 Suppl B:8-16. doi: 10.1093/eurheartj/17.suppl_b.8. Eur Heart J. 1996. PMID: 8733065 Review.

9

Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.

Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR. Lowes BD, et al. Among authors: bristow mr. J Am Coll Cardiol. 2000 Aug;36(2):501-8. doi: 10.1016/s0735-1097(00)00759-2. J Am Coll Cardiol. 2000. PMID: 10933364 Free article. Clinical Trial.

10

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.

Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ; Moxonidine Safety and Efficacy (MOXSE) Investigators. Swedberg K, et al. Among authors: bristow mr. Circulation. 2002 Apr 16;105(15):1797-803. doi: 10.1161/01.cir.0000014212.04920.62. Circulation. 2002. PMID: 11956122 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

439 results

Search Page

Filters